Factors That Increase the Risk of Myopathy in People Taking Statins Philip J. Barter, and Kerry-Anne Rye Circulation 2006;114:1315- 1320 5) Jones PH, Davidson.

Slides:

Advertisements

Similar presentations

Residual risk: Is LDL target enough?

Advertisements

Protecting the heart and the kidney: Implications from the SHARP trial Dr. Christina Reith University of Oxford United Kingdom.

Statins in the Primary and Secondary Prevention of CAD Prof. M. Ishaq Karachi Institute of Heart Diseases.

Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.

Lipid Disorders and Management in Diabetes

Slide Source LipidsOnline CO O C CH 3 COOCH CH 3 Cl CH 3 OC COOC 2 H 5 CH 3 Cl CH 3 OCH 2 CH 3 COOH CH 3 C Fenofibrate Clofibrate.

TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.

The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia James Shepherd, M.D., Stuart M. Cobbe, M.D., Ian Ford, Ph.D., Christopher.

CHOLESTEROL LOWERING.

TC LDL- C HDL- C Nonfatal MI/CHD death CHD death All- cause mortality *As compared to placebo. † P= CARE: Effect of Lipid Lowering on Lipid Values.

VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.

Slide Source: Lipids Online Slide Library Prospective Pravastatin Pooling Project: Coronary Event Rates in CARE and LIPID Patients.

CE-1 CRESTOR ® Clinical Development Efficacy James W. Blasetto, MD, MPH Senior Director, Clinical Research.

Role of Rosuvastatin in the Treatment of Dyslipidemia

1 LDL-C and CV Risk: What We Know and Don't Know Joseph J. Saseen, PharmD, FCCP, BCPS, CLS Associate Professor Clinical Pharmacy and Family Medicine University.

HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.

Lipid Lowering Substudy Trial of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288: ALLHAT- LLT.

Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.

Modern Management of Cholesterol in the High-Risk Patient.

Fenofibrate Intervention and Event Lowering in Diabetes FIELDFIELD Presented at The American Heart Association Scientific Sessions, November 2005 Presented.

VBWG HPS. Lancet. 2003;361: Gæde P et al. N Engl J Med. 2003;348: Recent statin trials: Reduction in primary outcome in patients with diabetes.

Slide 1 EZT 2002-W-6022-SS Ezetimibe Co-administered with Statins: Efficacy and Tolerability Copyright © 2003 MSP Singapore Company, LLC. All rights reserved.

Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.

Slide Source: Lipids Online Slide Library Collaborative Atorvastatin Diabetes Study (CARDS) Type 2 diabetes mellitus Men and women.

HPS: Heart Protection Study Purpose To determine whether simvastatin reduces mortality and vascular events in patients with and without coronary disease,

Slide 1 Downloaded from Ezetimibe Factorial Coadministration Studies.

The Prospective Pravastatin Pooling Project L I P I D CARECARE PPP Project Investigators Am J Cardiol 1995; 76:899–905.

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

OVERALL SURVIVAL Adapted from Scandinavian Simvastatin Survival Study Group Lancet 1994;344: % of patients alive Simvastatin (n=2221)

SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 2 ARBITER-2 Trial Presented at The American Heart Association Scientific.

AA-2-1 Jerome D. Cohen, MD, FACC, FACP Professor of Internal Medicine / Cardiology Director, Preventive Cardiology Programs St. Louis University Health.

LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.

Clinical Trial Results. org SAGE Trial Prakash Deedwania, MD; Peter H. Stone, MD; C. Noel Bairey Merz, MD; Juan Cosin-Aguilar, MD; Nevres Koylan, MD; Don.

Endocrinologic & Metabolic Drugs Advisory Committee Meeting

Atorvastatin: Effective Therapy for a Broad Range of Dyslipidemias

The IDEAL Cholesterol Christopher Cannon, M.D. TIMI Study Group Brigham and Women’s Hospital Cannon CP. JAMA 2005;294:

Trial profile The FIELD study investigators, Lancet Published online November 14, 2005.

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults Scott W. Rypkema, M.D.

Date of download: 5/31/2016 Copyright © The American College of Cardiology. All rights reserved. From: Optimal low-density lipoprotein is 50 to 70 mg/dl:

Double-blind, randomized trial in 4,162 patients with Acute Coronary Syndrome

Christie M. Ballantyne, MD

Pravastatin in Elderly Individuals at Risk of Vascular Disease

Triglycerides Cholesterol HDL-C or N NIDDM N or or N IDDM.

The Anglo Scandinavian Cardiac Outcomes Trial

AIM HIGH Niacin plus Statin to prevent vascular events

HDL cholesterol and cardiovascular risk Epidemiological evidence

HDL cholesterol and cardiovascular risk

Scandinavian Simvastatin Survival Study (4S)

AIM-HIGH Niacin Plus Statin to Prevent Vascular Events

Oxford Niacin Trial.

Cholesterol, CV Events, and PCSK9 Inhibitors Highlights From the AHA

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

TNT Study: Baseline Characteristics of the Patients

Statins and New-Onset Diabetes REAL Updates and Clinical Implications

Diabetes Increases Risk of CVD

An Update on PCSK9 Inhibitors

PCSK9 Inhibitors and Cardiovascular Outcomes

Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?

LDL Cholesterol.

How to Optimize Cholesterol Management in High-Risk CV Patients

LRC-CPPT and MRFIT Content Points:

Reducing Risk for CV Outcomes

Potential mechanisms whereby statins may reduce the risk of stroke

An Update on PCSK9 Inhibitors

LDL - How low can you go? Terry Jacobsen, MD

Opening a New Lipid “Apo-thecary”: Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk Terry.

The following slides highlight a report on a presentation at the American College of Cardiology 2004, Scientific Sessions, in New Orleans, Louisiana on.

Presentation transcript:

Factors That Increase the Risk of Myopathy in People Taking Statins Philip J. Barter, and Kerry-Anne Rye Circulation 2006;114: ) Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. 2005; 95: 120–122. 6) Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003; 289: 1681– ) Lee AJ, Maddix DS. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother. 2001; 35: 26–31. 8) Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E, Marz W, Reckless JP, Stein EA. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003; 163: 553–564. 9) Foody JM, Krumholz HM. Are statins indicated for the primary prevention of CAD in octogenarians? Antagonist viewpoint. Am J Geriatr Cardiol. 2003; 12: 357– ) Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Hawkins CM, Keech A, Packard C, Simes J, Byington R, Furberg CD. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation. 2000; 102: 1893– ) Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation. 2004; 109 (suppl I): III-50–III-57.

Relation between reduction in incidence of CV events and mean LDL cholesterol reduction in major statin trials Philip J. Barter, and Kerry-Anne Rye Circulation 2006;114:

Event rates plotted vs LDL cholesterol levels during statin therapy in secondary-prevention studies Philip J. Barter, and Kerry-Anne Rye Circulation 2006;114:

Coronary heart disease event rate in men and women as a function of HDL cholesterol levels in the Framingham Heart Study Philip J. Barter, and Kerry-Anne Rye Circulation 2006;114:

Cardiovascular event rates in statin trials as a function of the baseline level of HDL cholesterol in the placebo and active treatment arms (pravastatin 40 mg in WOSCOPS) Philip J. Barter, and Kerry-Anne Rye Circulation 2006;114:

Cardiovascular event rates in statin trials as a function of the baseline level of HDL cholesterol in the placebo and active treatment arms (pravastatin 40 mg in the LIPID and CARE trials) Philip J. Barter, and Kerry-Anne Rye Circulation 2006;114:

Cardiovascular event rates in statin trials as a function of the baseline level of HDL cholesterol in the placebo and active treatment arms (simvastatin 40 mg in the HPS) Philip J. Barter, and Kerry-Anne Rye Circulation 2006;114: